Open AccessEmerging resistance to directly-acting antiviral therapy in treatment of chronic Hepatitis C infection—A brief review of literature
Author(s) -
Mohit Bhatia,
Ekta Gupta
Publication year - 2020
Publication title -
journal of family medicine and primary care
Language(s) - English
Resource type - Journals
eISSN - 2278-7135
pISSN - 2249-4863
DOI - 10.4103/jfmpc.jfmpc_943_19
Subject(s) - medicine , hepatocellular carcinoma , hepatitis c virus , cirrhosis , hepatitis c , chronic infection , immunology , drug resistance , antiviral therapy , virus , interferon , virology , intensive care medicine , chronic hepatitis , immune system , microbiology and biotechnology , biology
Hepatitis caused by Hepatitis C virus (HCV) is a major cause of chronic liver disease. HCV is transmitted by injection drug use, blood transfusion, hemodialysis, organ transplantation and less frequently sexual intercourse. It has been recognized as a global health problem because of the progression to cirrhosis and hepatocellular carcinoma. Globally, about 170 million people are infected with HCV. Since the discovery of this virus in 1989, the clinical management of chronic hepatitis C infection has undergone a paradigm shift from alpha interferon to direct-acting antiviral (DAA) therapy. However, resistance to many of these antiviral agents has been reported increasingly from all over the globe. This review article focuses on the emerging HCV resistance to DAAs and the relevance of in vitro DAA resistance testing in clinical practice.